• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Theralase Technologies Inc (OP:TLTFF)

    0.1463 +0.0015 (+1.04%)
    Streaming Delayed Price Updated: 10:42 AM EDT, Oct 9, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Theralase Technologies Inc

    < Previous 1 2 3 Next >
    Independent Research Demonstrates Ruvidar(R) Effective in the Destruction of Herpes Simplex Virus
    Toronto, Ontario--(Newsfile Corp. - September 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical... 
    Via Newsfile
    Topics Derivatives
    Theralase(R) Extends Warrants
    Toronto, Ontario--(Newsfile Corp. - August 29, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage... 
    Via Newsfile
    Theralase(R) Releases 2Q2025 Financial Statements
    Toronto, Ontario--(Newsfile Corp. - August 26, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage... 
    Via Newsfile
    CORRECTING AND REPLACING: Theralase(R) Demonstrates Effective Treatment of Herpes
    Via ACCESS Newswire
    Theralase(R) Launches New Clinical Study Site in Canada
    Via ACCESSWIRE
    Theralase(R) Closes Non-Brokered Private Placement
    Toronto, Ontario--(Newsfile Corp. - July 28, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage... 
    Via Newsfile
    Theralase(R) Extends Warrants
    Toronto, Ontario--(Newsfile Corp. - June 27, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical... 
    Via Newsfile
    Theralase(R) Closes Non-Brokered Private Placement
    Toronto, Ontario--(Newsfile Corp. - June 17, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage... 
    Via Newsfile
    Theralase Completes Annual General and Special Meeting
    Toronto, Ontario--(Newsfile Corp. - June 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical... 
    Via Newsfile
    Theralase Annual General Meeting
    Toronto, Ontario--(Newsfile Corp. - June 5, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a... 
    Via Newsfile
    Theralase(R) 1Q2025 Financial Statements
    Toronto, Ontario--(Newsfile Corp. - May 30, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a... 
    Via Newsfile
    CORRECTION FROM SOURCE: Theralase to Present Groundbreaking Research at ASTRO 2025
    This Press Release removes references to preclinical data that has not yet been presented.Toronto, Ontario--(Newsfile Corp. - May 29, 2025)... 
    Via Newsfile
    Theralase to Present Groundbreaking Research at ASTRO 2025
    Toronto, Ontario--(Newsfile Corp. - May 28, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a... 
    Via Newsfile
    Theralase Provides Corporate Update
    Toronto, Ontario--(Newsfile Corp. - May 20, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a... 
    Via Newsfile
    Theralase Clinical Data Presented at Canadian Bladder Cancer Forum and American Urological Association
    Toronto, Ontario--(Newsfile Corp. - May 5, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a... 
    Via Newsfile
    Theralase Discovers New Mechanism of Action of Lead Drug
    Toronto, Ontario--(Newsfile Corp. - April 28, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a... 
    Via Newsfile
    Theralase(R) Closes Non-Brokered Private Placement
    Toronto, Ontario--(Newsfile Corp. - April 14, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a... 
    Via Newsfile
    Ruvidar More Effective in the Treatment of Herpes than FDA-Approved Treatments
    Toronto, Ontario--(Newsfile Corp. - April 10, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical... 
    Via Newsfile
    Ruvidar Demonstrates 7 Year Complete Response
    Toronto, Ontario--(Newsfile Corp. - April 7, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical... 
    Via Newsfile
    Ruvidar Effective in the Treatment of Herpes
    Toronto, Ontario--(Newsfile Corp. - March 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a... 
    Via Newsfile
    Theralase(R) Releases 2024 Annual Financial Statements
    Toronto, Ontario--(Newsfile Corp. - March 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a... 
    Via Newsfile
    Theralase(R) Closes Non-Brokered Private Placement
    Toronto, Ontario--(Newsfile Corp. - March 11, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a... 
    Via Newsfile
    Theralase(R) Therapy Improves Motor and Non-Motor Function in Parkinson's Patients
    Toronto, Ontario--(Newsfile Corp. - March 10, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a... 
    Via Newsfile
    Theralase(R) Demonstrates Efficacy of Rutherrin(R) in Destruction of Non-Hodgkin's Lymphoma
    Toronto, Ontario--(Newsfile Corp. - February 25, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical... 
    Via Newsfile
    Topics Death
    Theralase(R) Demonstrates Effective Treatment of Herpes
    Via ACCESS Newswire
    Theralase(R) Releases Latest Research on Inactivation of Herpes Simplex Viruses
    Via ACCESS Newswire
    Theralase(R) Interim Clinical Data to be Presented at the 2025 AUA Annual Meeting
    Via ACCESS Newswire
    Theralase(R) Launches Three New Clinical Study Sites in USA
    Via ACCESSWIRE
    Theralase(R) Release’s 3Q2024 Financial Statements
    Via ACCESSWIRE
    Theralase(R) Closes Non-Brokered Private Placement
    Via ACCESSWIRE
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.